No overall health benefit from lower blood pressure targets

No evidence of a difference in total mortality and serious adverse events was found between treating to a lower or to a standard BP target in people with hypertension and CV disease. This suggested no net health benefit from a lower systolic BP target despite the small absolute reduction in total CV serious adverse events. There was very limited evidence on adverse events, which led to high uncertainty. Predefined subgroup analyses in older people, those with diabetes, or based on participant’s sex did not suggest any differences in these conclusions.